HLB said it opened a new office in the Cambridge Innovation Center (CIC) in Boston, U.S. to bolster the collaboration and communication between HLB and its U.S. subsidiaries, such as Immunomic Therapeutics, while also supporting its group companies' entry into international markets.HLB's new office
The International Nonproprietary Name (INN) of LAPS Glucagon analog (code name HM15136), which Hanmi Pharm is developing as an innovative new drug for treating congenital hyperinsulinemia, has been fixed as “efpegerglucagon.”Hanmi Pharm said Thursday that the World Health Organization has officially
Handok and Swedish Orphan Biovitrum (Sobi) said they have officially inaugurated their Korean joint venture, Handok-Sobi.Sobi is a global biopharmaceutical company specializing in rare diseases, providing innovative treatments in hematology, immunology, and specialized therapies. With 1,800 employee
GC Cell said its U.S. affiliate Artiva Biotherapeutics has begun administering the first dose to a participant in a phase 1 clinical trial. This trial investigates the combination of AlloNK (AB-101) and rituximab as a potential treatment for lupus nephritis.Lupus nephritis is a complication of syste
Celltrion said it has been awarded the national tender for the world's only infliximab subcutaneous (SC) formulation, Remsima SC, in Denmark, a key Nordic market. Under the agreement, Remsima SC will be supplied to Denmark for one year starting this month.Celltrion launched Remsima SC in Norway in F
A clinical study has shown that Orafang tablets are safe for people in their 40s and 50s and for the very elderly aged 70 or more.Pharmbio Korea said Tuesday that it presented clinical results at the Seventh International Meeting on Intestinal Diseases, which was held in conjunction with the Annual
BNC Korea said it secured exclusive distribution rights in five Asian countries for Danish biotech firm Kariya's KP405 and KP404, both Alzheimer's and Parkinson's drug candidates that can cross the blood-brain barrier.The agreement, which encompasses Korea, Singapore, Thailand, Indonesia, and Malays
AstraZeneca Korea's Tagrisso (osimertinib) has expanded its indication to include the first-line treatment of EGFR-mutated non-squamous NSCLC.The Ministry of Food and Drug Safety on Monday approved Tagrisso in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment o
Daewoong Bio said the company has changed its entire lineup of tablets containing telmisartan, an ingredient for treating hypertension, into moisture-resistant tablets to solve the problem of hygroscopicity (the property of absorbing moisture) and renewed the bottle packaging.The ingredient telmisar
MSD Korea said Tuesday that it has received approval from the Ministry of Food and Drug Safety (MFDS) to expand the indication of its anti-PD-1 immuno-oncology drug Keytruda (pembrolizumab) as a combination therapy with chemoradiotherapy for treating patients with FIGO 2014 stage III-IVA cervical ca
EuBiologics said on Tuesday that its Euvichol-S, a simplified formulation of the oral cholera vaccine co-developed with the International Vaccine Institute (IVI), has obtained prequalification (PQ) certification from the World Health Organization (WHO).Euvichol-S is a new oral cholera vaccine that h
DongKoo Bio & Pharma, a Korean company known for its dermatological products, has announced a strategic investment of 10 billion won ($7.2 million) into Qurient, a local biotech, becoming its largest shareholder.Through this latest investment, DongKoo will acquire approximately 2.56 million new shar
Handok said it finalized an exclusive distribution and supply agreement with Nxera Pharma Korea, the offshoot of a Japan-based pharmaceutical company Nxera, for Pivlaz, a drug designed to prevent cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysm
Pharmaceutical products are difficult to develop, manufacture, and produce, as they are directly linked to human lives. Moreover, the importance of drug distribution management has been emphasized recently. That’s because, unlike in the past, when synthetic chemical drugs were the mainstay, biologic
Yuyu Pharma said its contract manufacturing organization (CMO) business, a new growth engine, is on a roll with a series of contract signings.This month, the company signed new CMO agreements with 10 pharmaceutical companies for manufacturing Fexogien Tab. (fexofenadine hydrochloride), an antihistam
OliX Pharmaceuticals, a Korean biotech firm specializing in RNA interference technologies, recently announced the promising results of its hair loss treatment, OLX104C, at the 13th World Congress for Hair Research (WCHR 2024) held in Texas, the U.S. from April 6-9.The WCHR, hosted by the Internation
PharmaEssentia Korea said it hosted a myeloproliferative neoplasms (MPN) forum to share the latest insights on Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV) on Thursday last week.The forum featured two world-renowned experts in the field of MPN -- Professor Hans Carl Hass
Janssen's Rybrevant (amivantamab), a treatment for EGFR exon20 insertion non-small cell lung cancer (NSCLC), a rare form of lung cancer with a poor prognosis, is making its third attempt to get reimbursement in Korea.The drug’s third challenge for insurance coverage comes when the “nominality” of th
NKMAX, a local biotech firm specializing in NK cell therapy, announced plans to file an objection to its potential delisting from the Korea Exchange (KRX).The company, which has been listed on the Kosdaq since August 2018, is facing delisting due to significant operational challenges.On March 5, NKM
GSK's Shingrix, the world's only shingles vaccine that can be given to immunocompromised individuals such as cancer patients, is notorious for causing pain, unlike any other vaccine, from the moment it is given to three to four days afterward.So why is it so painful to receive Shingrix, a recombinan